COMPARISON OF AN AGGRESSIVE (UNITED-STATES) AND A LESS AGGRESSIVE (CANADIAN) POLICY FOR CHOLESTEROL SCREENING AND TREATMENT

被引:32
作者
KRAHN, M [1 ]
NAYLOR, CD [1 ]
BASINSKI, AS [1 ]
DETSKY, AS [1 ]
机构
[1] SUNNYBROOK HLTH SCI CTR, TORONTO, ONTARIO, CANADA
关键词
D O I
10.7326/0003-4819-115-4-248
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: To determine the point at which adverse quality-of-life effects engendered by an aggressive cholesterol-lowering strategy dictate the use of a less aggressive approach. Design: Decision analysis was used to compare the effects of the National Cholesterol Education Program (NCEP) guidelines, an aggressive program, with those of the Canadian Task Force on the Periodic Health Examination (CTF) guidelines, a more conservative program. Quality-adjusted life expectancy was calculated for a theoretical cohort of middle-aged men treated according to each program using Markov cohort analysis. Measurements: Guidelines were applied to the population of the Lipid Research Clinics Coronary Primary Prevention Trial (LRC-CPPT), under the assumption that cholesterol levels had the distribution of the age- and sex-matched general population. Outcomes were calculated using a three-state (health, coronary heart disease, and death) Markov model. State transition probabilities were calculated using bivariate (age and cholesterol) proportional hazards and logistic regression functions. Main Results: The result was a "toss-up"; the number of expected quality-adjusted life years was similar for both programs at all time intervals, although the conservative program was consistently slightly favored. The result was very sensitive to the disutility of dietary therapy (threshold value, 0.0014 compared with the baseline estimate of 0.02) but was also affected by the time frame of the analysis and the rate at which adverse effects of treatment decline. Conclusions: Even small disutilities associated with treatment may outweigh the benefits of aggressive cholesterol-lowering strategies. Research should be directed toward measuring these disutilities and finding ways to reduce their size. Incorporation of the disutility of treatment into policy formulation may result in less interventionist and less costly policies.
引用
收藏
页码:248 / 255
页数:8
相关论文
共 33 条
  • [1] HYPERTENSION CONTROL AT WORK SITE
    ALDERMAN, MH
    DAVIS, TK
    [J]. JOURNAL OF OCCUPATIONAL AND ENVIRONMENTAL MEDICINE, 1976, 18 (12) : 793 - 796
  • [2] CHOLESTEROL AND MORTALITY - 30 YEARS OF FOLLOW-UP FROM THE FRAMINGHAM-STUDY
    ANDERSON, KM
    CASTELLI, WP
    LEVY, D
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1987, 257 (16): : 2176 - 2180
  • [3] THE MARKOV PROCESS IN MEDICAL PROGNOSIS
    BECK, JR
    PAUKER, SG
    [J]. MEDICAL DECISION MAKING, 1983, 3 (04) : 419 - 458
  • [4] BENEFICIAL-EFFECTS OF COMBINED COLESTIPOL-NIACIN THERAPY ON CORONARY ATHEROSCLEROSIS AND CORONARY VENOUS BYPASS GRAFTS
    BLANKENHORN, DH
    NESSIM, SA
    JOHNSON, RL
    SANMARCO, ME
    AZEN, SP
    CASHINHEMPHILL, L
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1987, 257 (23): : 3233 - 3240
  • [6] ESTIMATING THE IMPACT OF RISK FACTOR MODIFICATION PROGRAMS
    BROWNER, WS
    [J]. AMERICAN JOURNAL OF EPIDEMIOLOGY, 1986, 123 (01) : 143 - 153
  • [7] CLEEMAN JI, 1988, ARCH INTERN MED, V148, P36, DOI 10.1001/archinte.148.1.36
  • [8] CORONARY RISK-FACTORS AND SURVIVAL PROBABILITY FROM CORONARY AND OTHER CAUSES OF DEATH
    FARCHI, G
    MENOTTI, A
    CONTI, S
    [J]. AMERICAN JOURNAL OF EPIDEMIOLOGY, 1987, 126 (03) : 400 - 408
  • [9] HELSINKI HEART-STUDY - PRIMARY-PREVENTION TRIAL WITH GEMFIBROZIL IN MIDDLE-AGED MEN WITH DYSLIPIDEMIA - SAFETY OF TREATMENT, CHANGES IN RISK-FACTORS, AND INCIDENCE OF CORONARY HEART-DISEASE
    FRICK, MH
    ELO, O
    HAAPA, K
    HEINONEN, OP
    HEINSALMI, P
    HELO, P
    HUTTUNEN, JK
    KAITANIEMI, P
    KOSKINEN, P
    MANNINEN, V
    MAENPAA, H
    MALKONEN, M
    MANTTARI, M
    NOROLA, S
    PASTERNACK, A
    PIKKARAINEN, J
    ROMO, M
    SJOBLOM, T
    NIKKILA, EA
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1987, 317 (20) : 1237 - 1245
  • [10] GARBER AM, 1989, COSTS EFFECTIVENESS